<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="191962">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593554</url>
  </required_header>
  <id_info>
    <org_study_id>0704-19 IUCRO-0184</org_study_id>
    <nct_id>NCT00593554</nct_id>
  </id_info>
  <brief_title>Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies</brief_title>
  <official_title>A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34 Cells in Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherif S. Farag</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an
      improvement in treatment-related mortality (TRM) rate at 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date type="Actual">August 7, 2007</start_date>
  <completion_date type="Actual">May 5, 2016</completion_date>
  <primary_completion_date type="Actual">May 5, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if haplotype-mismatched HSCT is associated with a ≤40% treatment-related mortality (TRM) rate at 6 months after transplantation; a TRM ≥60% being considered unacceptable.</measure>
    <time_frame>thru 6 months after transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe regimen-related toxicity</measure>
    <time_frame>baseline through end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the time to engraftment of neutrophils and platelets following haplotype-mismatched CD34 selected cells</measure>
    <time_frame>baseline through end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the risks of acute and chronic GvHD following infusion of highly purified CD34 cells</measure>
    <time_frame>baseline through end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the frequency and type of infections occurring within the first year following transplantation.</measure>
    <time_frame>Day 0 through 1 year post transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe and gather preliminary data on thymic immune reconstitution following transplantation in patients receiving and not receiving KGF.</measure>
    <time_frame>Day -11, -10 and -9 pre transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the correlation between KIR-ligand mismatching and KIR gene mismatching between donor and recipient and outcome, including relapse rate, event-free survival, and overall survival.</measure>
    <time_frame>Baseline until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the rate of progression-free survival and overall survival</measure>
    <time_frame>Baseline until death</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplasia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total body Irradiation; Thiotepa; Fludarabine; Rabbit ATG;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palifermin; Total Body Irradiation; Thiotepa; Fludarabine; Rabbit ATG</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>8 Gy on Day -9</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>5 mg/kg/d on Day -8 to -7</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>40 mg/m2/d on Day -6 to -3</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabbit ATG</intervention_name>
    <description>2.5 mg/kg/d on Day -5 to -2</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Antithymocyte globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <description>60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Recombinant human keratinocyte growth factor</other_name>
    <other_name>Kepivance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically documented AML, ALL, MDS, CML, Acute myeloid
             leukemia (AML) with one or more of the following criteria

               -  CR 1 with poor risk features

               -  CR 2, or higher order CR

          -  Acute lymphoblastic leukemia (ALL) with one of the following criteria

               -  CR 1 with poor risk features

               -  CR 2, or higher order CR

          -  Myelodysplasia, RAEB I

          -  Donor has been identified

          -  Age ≤ 65 years.

          -  Performance Status 0-1.

        Exclusion Criteria:

          -  Patients relapsing &lt;6 months after autologous SCT are not eligible.

          -  Patients with active infections requiring oral or intravenous antibiotics are not
             eligible for enrollment until resolution of infection.

          -  Non-pregnant and non-nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherif Farag, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.iu.edu/patients/trials/findtrials.php?category=disease</url>
    <description>IU Simon Cancer Center &quot;Find a Clinical Trial&quot;</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>January 4, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Sherif S. Farag</investigator_full_name>
    <investigator_title>Lawrence H. Einhorn Professor of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
